PL2908805T3 - Formulacje lewodopy do szybkiego złagodzenia choroby parkinsona - Google Patents
Formulacje lewodopy do szybkiego złagodzenia choroby parkinsonaInfo
- Publication number
- PL2908805T3 PL2908805T3 PL13849388T PL13849388T PL2908805T3 PL 2908805 T3 PL2908805 T3 PL 2908805T3 PL 13849388 T PL13849388 T PL 13849388T PL 13849388 T PL13849388 T PL 13849388T PL 2908805 T3 PL2908805 T3 PL 2908805T3
- Authority
- PL
- Poland
- Prior art keywords
- parkinson
- disease
- rapid relief
- levodopa formulations
- levodopa
- Prior art date
Links
- WTDRDQBEARUVNC-LURJTMIESA-N L-DOPA Chemical compound OC(=O)[C@@H](N)CC1=CC=C(O)C(O)=C1 WTDRDQBEARUVNC-LURJTMIESA-N 0.000 title 1
- WTDRDQBEARUVNC-UHFFFAOYSA-N L-Dopa Natural products OC(=O)C(N)CC1=CC=C(O)C(O)=C1 WTDRDQBEARUVNC-UHFFFAOYSA-N 0.000 title 1
- 208000018737 Parkinson disease Diseases 0.000 title 1
- 238000009472 formulation Methods 0.000 title 1
- 229960004502 levodopa Drugs 0.000 title 1
- 239000000203 mixture Substances 0.000 title 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
- A61K31/19—Carboxylic acids, e.g. valproic acid
- A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
- A61K31/197—Carboxylic acids, e.g. valproic acid having an amino group the amino and the carboxyl groups being attached to the same acyclic carbon chain, e.g. gamma-aminobutyric acid [GABA], beta-alanine, epsilon-aminocaproic acid or pantothenic acid
- A61K31/198—Alpha-amino acids, e.g. alanine or edetic acid [EDTA]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
- A61K31/19—Carboxylic acids, e.g. valproic acid
- A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
- A61K31/197—Carboxylic acids, e.g. valproic acid having an amino group the amino and the carboxyl groups being attached to the same acyclic carbon chain, e.g. gamma-aminobutyric acid [GABA], beta-alanine, epsilon-aminocaproic acid or pantothenic acid
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/007—Pulmonary tract; Aromatherapy
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/10—Dispersions; Emulsions
- A61K9/12—Aerosols; Foams
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
- A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
- A61K9/1605—Excipients; Inactive ingredients
- A61K9/1617—Organic compounds, e.g. phospholipids, fats
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
- A61P25/16—Anti-Parkinson drugs
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/007—Pulmonary tract; Aromatherapy
- A61K9/0073—Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy
- A61K9/0075—Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy for inhalation via a dry powder inhaler [DPI], e.g. comprising micronized drug mixed with lactose carrier particles
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/007—Pulmonary tract; Aromatherapy
- A61K9/0073—Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy
- A61K9/0078—Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy for inhalation via a nebulizer such as a jet nebulizer, ultrasonic nebulizer, e.g. in the form of aqueous drug solutions or dispersions
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/007—Pulmonary tract; Aromatherapy
- A61K9/0073—Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy
- A61K9/008—Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy comprising drug dissolved or suspended in liquid propellant for inhalation via a pressurized metered dose inhaler [MDI]
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Epidemiology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Pulmonology (AREA)
- Neurology (AREA)
- Neurosurgery (AREA)
- Biomedical Technology (AREA)
- Otolaryngology (AREA)
- Dispersion Chemistry (AREA)
- General Chemical & Material Sciences (AREA)
- Psychology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- Molecular Biology (AREA)
- Biophysics (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Medicinal Preparation (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Applications Claiming Priority (5)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201261716740P | 2012-10-22 | 2012-10-22 | |
| US201361813605P | 2013-04-18 | 2013-04-18 | |
| US201361813725P | 2013-04-19 | 2013-04-19 | |
| PCT/US2013/065838 WO2014066208A1 (en) | 2012-10-22 | 2013-10-21 | Levodopa formulations for rapid relief of parkinson's disease |
| EP13849388.7A EP2908805B1 (en) | 2012-10-22 | 2013-10-21 | Levodopa formulations for rapid relief of parkinson's disease |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| PL2908805T3 true PL2908805T3 (pl) | 2021-12-27 |
Family
ID=50545142
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| PL13849388T PL2908805T3 (pl) | 2012-10-22 | 2013-10-21 | Formulacje lewodopy do szybkiego złagodzenia choroby parkinsona |
Country Status (18)
| Country | Link |
|---|---|
| US (1) | US20150328175A1 (pl) |
| EP (2) | EP2908805B1 (pl) |
| JP (2) | JP2016500690A (pl) |
| KR (2) | KR20210075224A (pl) |
| CN (2) | CN104884046A (pl) |
| AU (3) | AU2013334949B2 (pl) |
| BR (1) | BR112015009088A2 (pl) |
| CA (1) | CA2888994C (pl) |
| DK (1) | DK2908805T3 (pl) |
| ES (1) | ES2886529T3 (pl) |
| HK (2) | HK1212258A1 (pl) |
| MX (2) | MX2015005038A (pl) |
| NZ (1) | NZ708414A (pl) |
| PL (1) | PL2908805T3 (pl) |
| PT (1) | PT2908805T (pl) |
| RU (2) | RU2685718C2 (pl) |
| SG (2) | SG11201503129RA (pl) |
| WO (1) | WO2014066208A1 (pl) |
Families Citing this family (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP2908804A4 (en) * | 2012-10-22 | 2016-07-13 | Civitas Therapeutics Inc | REDUCTION OF VARIABILITY BETWEEN PATIENTS OF LEVODOPA PLASMA CONCENTRATIONS |
| BR112015010601B1 (pt) | 2012-11-09 | 2022-07-19 | Civitas Therapeutics, Inc. | Composição farmacêutica e uso da composição |
| BR112016024502A8 (pt) * | 2014-04-21 | 2021-06-29 | Civitas Therapeutics Inc | uso de uma dose de partículas finas (fdp) de levodopa na fabricação de um medicamento |
| BR112020013749A2 (pt) * | 2018-01-05 | 2020-12-01 | Impel Neuropharma, Inc. | dispensação intranasal de pó de levodopa por dispositivo olfativo de precisão |
| JP2021532098A (ja) | 2018-07-19 | 2021-11-25 | インペル ニューロファーマ インコーポレイテッド | パーキンソン病の治療のためのレボドパおよびドーパデカルボキシラーゼ阻害剤の呼吸管路送達 |
Family Cites Families (7)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US6254854B1 (en) | 1996-05-24 | 2001-07-03 | The Penn Research Foundation | Porous particles for deep lung delivery |
| US6858199B1 (en) | 2000-06-09 | 2005-02-22 | Advanced Inhalation Research, Inc. | High efficient delivery of a large therapeutic mass aerosol |
| US6514482B1 (en) | 2000-09-19 | 2003-02-04 | Advanced Inhalation Research, Inc. | Pulmonary delivery in treating disorders of the central nervous system |
| GB0027020D0 (en) * | 2000-11-03 | 2000-12-20 | Univ Manchester | Treatment of movement disorders |
| EP1531798B1 (en) * | 2002-03-20 | 2012-06-06 | Civitas Therapeutics, Inc. | Pulmonary delivery for levodopa |
| US7160913B2 (en) * | 2002-09-13 | 2007-01-09 | Thomas Jefferson University | Methods and kit for treating Parkinson's disease |
| GB2454480A (en) * | 2007-11-07 | 2009-05-13 | Vectura Group Plc | Pulmonary inhalation of levodopa containing compositions in the treatment of Parkinsons disease and other central nervous system disorders |
-
2013
- 2013-10-21 SG SG11201503129RA patent/SG11201503129RA/en unknown
- 2013-10-21 PL PL13849388T patent/PL2908805T3/pl unknown
- 2013-10-21 CN CN201380067424.3A patent/CN104884046A/zh active Pending
- 2013-10-21 BR BR112015009088A patent/BR112015009088A2/pt not_active Application Discontinuation
- 2013-10-21 AU AU2013334949A patent/AU2013334949B2/en active Active
- 2013-10-21 MX MX2015005038A patent/MX2015005038A/es active IP Right Grant
- 2013-10-21 RU RU2015119377A patent/RU2685718C2/ru active
- 2013-10-21 ES ES13849388T patent/ES2886529T3/es active Active
- 2013-10-21 EP EP13849388.7A patent/EP2908805B1/en active Active
- 2013-10-21 DK DK13849388.7T patent/DK2908805T3/da active
- 2013-10-21 SG SG10201804985QA patent/SG10201804985QA/en unknown
- 2013-10-21 PT PT138493887T patent/PT2908805T/pt unknown
- 2013-10-21 CA CA2888994A patent/CA2888994C/en active Active
- 2013-10-21 EP EP21177872.5A patent/EP3943080A1/en not_active Withdrawn
- 2013-10-21 CN CN201910981361.1A patent/CN110812350A/zh active Pending
- 2013-10-21 WO PCT/US2013/065838 patent/WO2014066208A1/en active Application Filing
- 2013-10-21 NZ NZ708414A patent/NZ708414A/en unknown
- 2013-10-21 MX MX2021014782A patent/MX2021014782A/es unknown
- 2013-10-21 KR KR1020217018284A patent/KR20210075224A/ko not_active Application Discontinuation
- 2013-10-21 KR KR1020157013721A patent/KR20150102960A/ko active Application Filing
- 2013-10-21 JP JP2015538101A patent/JP2016500690A/ja active Pending
-
2015
- 2015-04-21 US US14/691,793 patent/US20150328175A1/en not_active Abandoned
-
2016
- 2016-01-14 HK HK16100409.7A patent/HK1212258A1/xx unknown
- 2016-01-21 HK HK16100641.5A patent/HK1212623A1/zh unknown
-
2018
- 2018-05-15 JP JP2018093632A patent/JP2018150339A/ja active Pending
- 2018-10-24 AU AU2018253538A patent/AU2018253538B2/en active Active
-
2019
- 2019-04-12 RU RU2019111096A patent/RU2019111096A/ru unknown
-
2020
- 2020-10-09 AU AU2020250325A patent/AU2020250325A1/en not_active Abandoned
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| IL266648B (en) | A method for treating Parkinson's disease | |
| IL269511A (en) | New therapeutic approaches to treat Parkinson's disease | |
| HK1210968A1 (en) | Compositions and treatment for eye diseases and disorders | |
| ES2627541T8 (es) | Métodos para tratar la enfermedad de Parkinson | |
| HK1212623A1 (zh) | 用於快速緩解帕金森病的左旋多巴製劑 | |
| IL233572A0 (en) | A pharmaceutical preparation containing a mixture with fixed doses for the treatment of Parkinson's disease | |
| GB201206382D0 (en) | Parkinson's disease biomarker | |
| EP2678009A4 (en) | CYSTAMINE ANALOGS FOR THE TREATMENT OF PARKINSON'S DISEASE | |
| EP2906225A4 (en) | METHODS OF TREATING KENNEDY'S DISEASE | |
| EP2841077A4 (en) | NUTRITIONAL FIBER COMPOSITIONS FOR THE TREATMENT OF METABOLISM DISORDERS | |
| HK1199410A1 (en) | Composition for enhancing defenses of skin | |
| EP2854539A4 (en) | PHOSPHONATE DERIVATIVES FOR THE TREATMENT OF ALZHEIMER'S DISEASE | |
| PL2730279T3 (pl) | Preparaty cynakalcetu o natychmiastowym uwalnianiu | |
| TWI560195B (en) | Novel synthesis of 5-deoxy-5'-fluorocytidine compounds | |
| IL241482A0 (en) | A method for treating Parkinson's disease | |
| GB201205857D0 (en) | Skin care formulations |